+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

KOL Perspectives: Perceptions of recent & upcoming data for key HBV pipeline agents

  • ID: 4701810
  • Drug Pipelines
  • October 2018
  • Region: Global
  • 28 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Arbutus
  • Replicor
  • Roche
  • Spring Bank
  • MORE
Summary

This KOL Insight briefing focuses on KOLs views of recent & upcoming data for key HBV pipeline agents.

Questions topics -
  • Further Phase I data required for Roche’s capsid inhibitor RO7049389
  • Replicor’s US trial plans and transition from IV to subcutaneous REP 2139
  • Efficacy of Spring Bank’s inarigivir at 100mg in the Phase II ACHIEVE trial
  • Expected role for inarigivir in HBV
  • Efficacy of Arbutus’s Q2W IV ARB-1467
  • ARB-1467, TDF + Peg-IFN trial design, potential for functional cure, & regimen acceptability
  • Future development of Arbutus’s next-generation RNAi therapeutic AB-729For internal use only
Key Highlights
  • Divided views on most relevant Phase I data required to differentiate RO7049389 from JNJ-6379 & ABI-H0731, with most concluding that Phase I data is insufficien
  • KOLs agree Replicor is making positive steps towards REP 2139’s development, but similar efficacy & safety must be demonstrated in the US trials and for the SC formulation
  • Disagreement between US and EU KOLs over the improvement in efficacy of inarigivir at the 100mg dose.
Scope
  • The insight briefing is based on Sociable Pharma’s analysis of primary research with our HBV key opinion leaders (KOLs).
In total, we conducted interviews with 10 KOLs -
  • 5 Europe-based & 5 N. America-based
  • Interviews performed during Sept 2018
KOL data is analyzed to produce -
  • Charts summarizing KOL opinions
  • Chart call-outs of key information & details
  • KOL quotes
  • Summary of KOL reporting trends
  • Insight from Sociable Pharma's analysts
Reasons to Buy
  • Combines Qualitative & semi-quantitative insight from key opinion leaders on "recent & upcoming data for key HBV pipeline agents"
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of HBV
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Arbutus
  • Replicor
  • Roche
  • Spring Bank
  • MORE
  • Executive Summary
  • Background
  • Research Panel Composition
  • Results & Implications
  • Appendix
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Roche
  • Replicor
  • Spring Bank
  • Arbutus
Note: Product cover images may vary from those shown
Adroll
adroll